Saturday, November 21, 2026

Celltrion Holds on to No. 1 Spot in Asian Biosimilar Market Share ... Speeds Up Follow-On Product Launches

Input
2026-11-19 15:55:39
Updated
2026-11-19 15:55:39
[Financial News] Celltrion is strengthening its foothold in local markets, repeatedly holding on to the No. 1 market-share position for autoimmune disease and cancer biosimilars in major Asian markets including Singapore, Malaysia, Thailand and Hong Kong. It plans to sustain growth by launching high-margin follow-on products in succession.
According to IQVIA, a pharmaceutical market research firm, Celltrion’s Remsima (infliximab) product range (IV and SC), a treatment for autoimmune diseases, had a 95% market share in Singapore in the second quarter of this year. It also retained the top spot in prescriptions in Hong Kong (83%) and Malaysia (75%).
Cancer drugs are also performing strongly. Herzuma (trastuzumab), a treatment for breast and stomach cancer, maintained its lead with market shares of 67% in Hong Kong, 59% in Thailand and 52% in Malaysia. In Thailand, its share rose from 42% in the previous quarter to 59%, a 17-percentage-point gain in a single quarter that widened its lead over competing products. Truxima (rituximab), a treatment for blood cancers, strengthened its prescription lead in each market, with shares of 92% in Singapore, 78% in Thailand and 41% in Hong Kong.
In Malaysia, Vegzelma (bevacizumab), a treatment for metastatic colorectal and breast cancer, has been gaining ground. After ranking fourth in the local bevacizumab market in the fourth quarter of last year, Vegzelma rose to first place in the first quarter of this year and retained the lead in the second quarter with a 25% market share.
Celltrion cited its direct-sales strategy, centered on local subsidiaries, as the reason for these results. In Asian markets where tenders account for a large share of sales, the company has continued to win contracts by emphasizing its products’ competitiveness and reliable supply, while building trust by responding quickly to healthcare institutions’ needs. It is also expanding its engagement with healthcare professionals through collaboration with major hospitals and participation in local medical conferences.
The company plans to use the sales network it has built to sell new products. Since late last year, it has launched Omlyclo (omalizumab), a treatment for allergic diseases, and Steqeyma (ustekinumab), a treatment for autoimmune diseases, in Singapore and Malaysia, among other markets.
Further launches are also scheduled. Vegzelma will be launched in Hong Kong at the end of this month, followed by Stoboclo (denosumab), a treatment for bone diseases, in Thailand in December. In February next year, the company will introduce Eydenzelt (aflibercept), a treatment for eye diseases, in Singapore and Omlyclo in Thailand. The company expects growth in its Asian business to accelerate as sales of its higher-margin follow-on products expand into more markets.
A Celltrion representative said, “We plan to use the direct-sales capabilities of our local subsidiaries and the value of the Celltrion brand to secure early market traction for our high-margin follow-on product portfolio,” adding, “We will focus our local business capabilities on ensuring continued growth in our performance across Asia.”

[email protected] Jung Sang-hee Reporter